Selecta Biosciences (NASDAQ:SELB) released its earnings results on Thursday, March 15th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.56) by ($0.32), Bloomberg Earnings reports. Selecta Biosciences had a negative return on equity of 110.64% and a negative net margin of 31,556.04%. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $15.00 million.
NASDAQ SELB traded down $0.32 during trading hours on Friday, hitting $10.20. The company’s stock had a trading volume of 120,454 shares, compared to its average volume of 306,418. Selecta Biosciences has a 52 week low of $7.95 and a 52 week high of $24.02. The company has a quick ratio of 9.00, a current ratio of 9.00 and a debt-to-equity ratio of 0.41.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Polaris Venture Management Co. V L.L.C. lifted its position in shares of Selecta Biosciences by 18.2% during the 4th quarter. Polaris Venture Management Co. V L.L.C. now owns 1,924,151 shares of the company’s stock worth $18,876,000 after buying an additional 296,624 shares in the last quarter. Perceptive Advisors LLC lifted its position in shares of Selecta Biosciences by 45.8% during the 3rd quarter. Perceptive Advisors LLC now owns 1,162,325 shares of the company’s stock worth $21,212,000 after buying an additional 365,000 shares in the last quarter. BlackRock Inc. lifted its position in shares of Selecta Biosciences by 7.1% during the 4th quarter. BlackRock Inc. now owns 620,229 shares of the company’s stock worth $6,085,000 after buying an additional 41,264 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Selecta Biosciences by 1.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 365,138 shares of the company’s stock worth $7,131,000 after buying an additional 6,292 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Selecta Biosciences by 352.0% during the 4th quarter. Millennium Management LLC now owns 285,266 shares of the company’s stock worth $2,798,000 after buying an additional 222,152 shares in the last quarter. 50.16% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have recently issued reports on the stock. Zacks Investment Research downgraded Selecta Biosciences from a “hold” rating to a “strong sell” rating in a report on Wednesday, March 21st. BidaskClub upgraded Selecta Biosciences from a “buy” rating to a “strong-buy” rating in a report on Thursday, March 15th. Mizuho assumed coverage on Selecta Biosciences in a report on Monday, February 26th. They set a “buy” rating and a $30.00 price target for the company. ValuEngine downgraded Selecta Biosciences from a “sell” rating to a “strong sell” rating in a report on Friday, February 2nd. Finally, Canaccord Genuity reissued a “buy” rating and set a $30.00 price objective on shares of Selecta Biosciences in a research report on Thursday, January 18th. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus target price of $23.33.
COPYRIGHT VIOLATION NOTICE: This article was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another domain, it was stolen and reposted in violation of international copyright and trademark laws. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/07/selecta-biosciences-selb-announces-quarterly-earnings-results.html.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.
Receive News & Ratings for Selecta Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.